Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that it received written notification from the Nasdaq Listing Qualifications Department on March 12, 2026, indicating non-compliance with the minimum bid price requirement under Listing Rule 5550(a)(2). The company's American Depositary Shares (ADSs) had traded below $1.00 per share for 30 consecutive business days, triggering the deficiency notice.
The notice has no immediate effect on the listing or trading of Scinai's ADSs. The company has been granted a 180-day compliance period, through September 8, 2026, to regain compliance. To achieve this, the closing bid price of its ADSs must meet or exceed $1.00 for at least 10 consecutive business days during this period. If Scinai fails to meet this requirement, it may be eligible for an additional 180-day compliance period if it meets certain conditions, including the market value of its publicly held shares and other initial listing standards.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. Its pipeline includes therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. Additionally, the company owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO) that provides services to biotech and pharmaceutical companies.
The receipt of this non-compliance notice is significant for investors as it highlights the company's current stock price challenges. However, the 180-day window provides an opportunity for the company to take corrective actions, such as a reverse stock split or other strategies to boost the share price. The outcome of this compliance period could impact the company's listing status and investor confidence. For more details, the full press release is available at https://ibn.fm/faOR5.
Scinai's ability to regain compliance will be closely watched by the market, as failure could lead to delisting from Nasdaq, which might affect liquidity and the company's ability to raise capital. The company has not yet announced any specific plan to address the bid price deficiency, but the notice serves as a catalyst for management to evaluate options. Investors should monitor Scinai's upcoming announcements and share price performance leading up to the September deadline.
